The presence of DTCs at baseline and their eradication after NACT ± denosumab
TNBC, DTC-positive, DTC-positive breast cancer, breast cancer
BREAST CANCER
A total of 167 patients from the GeparX clinical trial were available for DTC-analysis (Fig. DTC-positivity at baseline and DTC-eradication after NACT ± denosumab. To monitor the rate of DTC-eradiation in response to NACT ± denosumab, we subsequently performed bone marrow re-puncture and DTC follow-up analysis in patients with a DTC-positive status at baseline. A total of 41/43 DTC-positive patients were available for this purpose. A patient was considered “DTC-eradicated”, if DTCs were initially present at baseline, followed by a negative DTC-status after NACT ± denosumab. We observed a high rate of DTC-eradication among baseline DTC-positive breast cancer patients after NACT ± denosumab (73.2%), which was consistent across the different subtypes of breast cancer (73.3% in HR + /HER2-; 70.0% in HER2 + ; 75.0% in TNBC; To sum up, we report a high rate of DTC-eradication (> 70%) in the total study population after NACT ± denosumab among baseline DTC-positive breast cancer patients.